# Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

> **NCT02101385** · PHASE2 · COMPLETED · sponsor: **Bryan Schneider, MD** · enrollment: 193 (actual)

## Conditions studied

- Malignant Neoplasm of Breast
- Breast Cancer

## Interventions

- **DRUG:** Genomically Directed Monotherapy
- **OTHER:** Observation/Standard Therapy

## Key facts

- **NCT ID:** NCT02101385
- **Lead sponsor:** Bryan Schneider, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-03
- **Primary completion:** 2021-02-21
- **Final completion:** 2022-09-09
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101385, "Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02101385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*